Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.71 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.59 |
| ▸ | PARP1 | P09874 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27621589 | 1.00 | CES2 (0.71) | CES2SRD5A2PARP1LMNANPSR1 | |
| Benzene SCHEMBL28007804 | 0.98 | CES2 (0.69) | CES2SRD5A2PARP1LMNANPSR1 | |
| Water SCHEMBL28050254 | 0.98 | CES2 (0.69) | CES2SRD5A2PARP1LMNANPSR1 | |
| Hydrochloric Acid SCHEMBL4372373 | 0.98 | CES2 (0.69) | CES2SRD5A2PARP1LMNANPSR1 | |
| Hydrochloric Acid SCHEMBL1267321 | 0.98 | CES2 (0.69) | CES2SRD5A2PARP1LMNANPSR1 | |
| Formic Acid SCHEMBL29537369 | 0.93 | CES2 (0.62) | CES2SRD5A2PARP1LMNANPSR1 | |
| Acetic Acid SCHEMBL10340449 | 0.93 | CES2 (0.62) | CES2SRD5A2PARP1LMNANPSR1 | |
| Trifluoroacetic Acid SCHEMBL6072041 | 0.93 | CES2 (0.62) | CES2SRD5A2PARP1LMNANPSR1 | |
| Butane SCHEMBL27384864 | 0.91 | ALDH1A1 (0.61) | CES2SRD5A2NPSR1PTGS1MAOB | |
| Propene SCHEMBL27375872 | 0.90 | CES2 (0.59) | CES2SRD5A2LMNANPSR1P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745138-A1 | THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| EP-4105213-B1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME | PHAROS IBIO CO LTD (KR) | 2026-04-15 | — | — | EP | claimed |
| US-20260070903-A1 | NOVEL PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, COMPRISING SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-12 | — | — | US | claimed |
| US-20250051293-A1 | NOVEL OXADIAZOLE DERIVATIVE AND USE THEREOF | CELROS BIOTECH (KR) | 2025-02-13 | — | — | US | claimed |
| CN-119371298-A | Method for efficiently synthesizing indenone compound | 南阳师范学院 | 2025-01-28 | — | — | CN | claimed |
| WO-2024242495-A1 | NOVEL COMPOUND FOR INHIBITING PROTEIN KINASES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 매직불릿테라퓨틱스 | 2024-11-28 | — | — | WO | claimed |
| EP-4431498-A1 | NOVEL OXADIAZOLE DERIVATIVE AND USE THEREOF | Celros Biotech (KR) | 2024-09-18 | — | — | EP | claimed |
| CN-118525010-A | Novel oxadiazole derivative and use thereof | 赛罗斯生物科技 | 2024-08-20 | — | — | CN | claimed |
| CN-113646307-B | Pyrido [3,4-d ] pyrimidin-8-one derivatives having protein kinase inhibitory activity and pharmaceutical compositions thereof | 韩国科学技术研究院 | 2024-07-30 | — | — | CN | claimed |
| US-11932646-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-03-19 | — | — | US | claimed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | claimed |
| EP-0998459-A2 | PYRIDINE DERIVATIVES | Novartis AG (CH) | 2000-05-10 | — | — | EP | claimed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | claimed |
| WO-2000009486-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-02-24 | — | — | WO | claimed |
| WO-2000008020-A2 | TRICYCLIC CARBOXAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-02-17 | — | — | WO | claimed |
| EP-0973767-A1 | INDAZOLES OF CYCLIC UREAS USEFUL AS HIV PROTEASE INHIBITORS | Dupont Pharmaceuticals Company (US) | 2000-01-26 | — | — | EP | claimed |
| US-5985867-A | TREATING HIV INFECTION | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-11-16 | — | — | US | claimed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | claimed |
| WO-1999002497-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 1999-01-21 | — | — | WO | claimed |
| WO-1998043969-A1 | INDAZOLES OF CYCLIC UREAS USEFUL AS HIV PROTEASE INHIBITORS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-10-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051293-A1 | NOVEL OXADIAZOLE DERIVATIVE AND USE THEREOF | NOX1, NOX3, NOX4 | CES2 2952/4885SRD5A2 1722/4885PARP1 1941/4885 |
| US-11932646-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | BCR, ABL1, MCL1 | CES2 2267/4885SRD5A2 3965/4885PARP1 2491/4885 |
| US-20260070903-A1 | NOVEL PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, COMPRISING SAME | CCNC, CKS1B, CKS2 | CES2 4658/4885SRD5A2 2172/4885PARP1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.